睿知中国疾病研究地图
候选清单0

邀请入组烟雾病早期I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Clinical Safety and Efficacy Evaluation of the Blood-cooling and Stasis-removing Formula as an Adjunct to Atorvastatin in the Treatment of Hemorrhagic Moyamoya Disease.

ClinicalTrials.gov 上登记的一项烟雾病开放试验,由江苏省人民医院(南医大一附院)牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方江苏省人民医院(南医大一附院)Jiangsu Province Hospital南京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07894640,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 2

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(2 项)收起清单
  1. 18 岁 至 60 岁;性别:不限

    登记记录的入选字段

  2. MRI and MRA findings: stenosis or occlusion of the terminal segment of the ICA and/or the initial segment of the ACA and/or MCA; abnormal vascular network in the basal ganglia (more than 2 obvious flow voids in the basal ganglia on one scan plane, suggesting the presence of an abnormal vascular network);

    入选标准第 3 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);既往治疗;日常活动能力;化验:血常规、肝肾功能;试验排除的其他疾病;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07894640,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. a) Age: 18-60 years old; b) Meets the Western medical diagnostic criteria for Moyamoya disease. Refer to the recommendations in the "Chinese Expert Consensus on the Diagnosis and Treatment of Moyamoya Disease and Moyamoya Syndrome (2024 Edition)": The diagnosis was confirmed as Moyamoya disease (8B22.B) and stroke (A07.01.01).
  2. DSA findings include: stenosis or occlusion of the distal ICA and/or the initial segments of the ACA and/or MCA; abnormal vascular network at the base of the skull in the arterial phase;
  3. MRI and MRA findings: stenosis or occlusion of the terminal segment of the ICA and/or the initial segment of the ACA and/or MCA; abnormal vascular network in the basal ganglia (more than 2 obvious flow voids in the basal ganglia on one scan plane, suggesting the presence of an abnormal vascular network);

排除标准:Exclusion Criteria:

  1. 1. Individuals with coexisting cognitive impairment or severe mental illness (ICD-10: F20-F48, F60-F69), such as Alzheimer's disease, other neurodegenerative diseases, Parkinson's disease, multiple sclerosis, demyelinating/hereditary central nervous system diseases, neurodevelopmental abnormalities, uncontrollable epilepsy, and other neurological diseases that researchers judge to significantly affect motor or cognitive function; 2. Pregnant women and breastfeeding patients; 3. Individuals with severe dysfunction of organs such as the heart, liver, kidneys, and lungs; individuals with severe congenital malformations (including congenital encephalocele, congenital hydrocephalus, congenital spina bifida, Argyll syndrome, etc., and congenital heart diseases with obvious circulatory and respiratory symptoms such as ventricular septal defect, tetralogy of Fallot, etc.); individuals with hematologic disorders; individuals with severe infections, tumors, etc.; individuals with positive HIV/syphilis/hepatitis B/C serological tests; 4. Currently participating in other drug clinical trials; 5. History of intolerance/allergy to any component of the investigational drug; 6. Hemorrhagic stroke within 12 months prior to enrollment; or a history of infarct-type moyamoya disease or other types of moyamoya disease; 7. Use of medications prohibited under this protocol within 30 days prior to enrollment; presence of alcohol or drug dependence; 8. Carotid/cerebrovascular surgery (including interventional treatment) may be required during the trial.

引自 ClinicalTrials.gov, NCT07894640, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07894640,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07894640